| Author (Person) | Jack, Andrew, Tait, Nikki |
|---|---|
| Series Title | Financial Times |
| Series Details | 9.7.09 |
| Publication Date | 09/07/2009 |
| Content Type | News |
|
Market entry of generic drugs is delayed and there is a decline in the number of novel medicines reaching the market, according to the European Commission's final report on competition in the pharmaceutical sector published July 2009. The sector inquiry suggests that company practices are among the causes, but does not exclude other factors such as shortcomings in the regulatory framework. As a follow up, the Commission intends to intensify its scrutiny of the pharmaceutical sector under EC antitrust law, including continued monitoring of settlements between originator and generic drug companies. The first antitrust investigations are already under way. The report also calls on Member States to introduce legislation to facilitate the uptake of generic drugs. The report notes near universal support amongst stakeholders for a Community Patent and specialised patent litigation system in Europe. Separately, the European Commission launched an investigation which will look into patent settlements around Servier’s blood pressure medicine perindopril. |
|
| Related Links |
|
| Subject Categories | Business and Industry, Internal Markets |
| Countries / Regions | Europe |
